Brief: Tuhura Biosciences Initiates Its Phase 3 Accelerated Approval Trial Of IFx-2.0
24/06/2025 13:09
June 24 (Reuters) - TuHURA Biosciences Inc HURA.O: TUHURA BIOSCIENCES INITIATES ITS PHASE 3 ACCELERATED APPROVAL TRIAL OF IFX-2.0 AS AN ADJUNCTIVE THERAPY TO KEYTRUDA® (PEMBROLIZUMAB) IN FIRST LINE TREATMENT FOR ADVANCED OR METASTATIC MERKEL CELL CARCINOMA TUHURA BIOSCIENCES INC: PRIMARY ENDPOINT OF OVERALL RESPONSE RATE (ORR) QUALIFIES FOR ACCELERATED APPROVAL PROCESS TUHURA BIOSCIENCES INC -KEY SECONDARY ENDPOINT OF PROGRESSION FREE SURVIVAL (PFS) MAY SATISFY REQUIREMENT FOR A POST CONFIRMATORY TRIAL Source text: ID:nPn3sVmWSa Further company coverage: HURA.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on TuHURA Biosciences
See all newsBrief: Tuhura Biosciences Receives Key U.S. Patent For Its Groundbreaking Delta Opioid Receptor Antibody Drug Conjugate Technology
TuHURA Biosciences Inc reports results for the quarter ended June 30 - Earnings Summary
Brief: Tuhura Biosciences Reports Second Quarter 2026 Financial Results And Provides A Corporate Update
TuHURA Biosciences Inc expected to post a loss of 14 cents a share - Earnings Preview
Brief: Tuhura Biosciences Inc Enters At The Market Offering Agreement With H.C. Wainwright & Co.